Objective: Approximately 50% of patients with severe symptomatic mitral regurgitation are deemed too high risk for surgery. The MitraClip procedure is a viable option for this population. Our goal was to assess outcomes and survival of patients who underwent the MitraClip procedure at an institution where mitral valve surgery is routinely performed. Methods: A retrospective study of patients undergoing the MitraClip procedure was performed. Baseline characteristics, perioperative outcomes, and follow-up echocardiographic and clinical outcomes were examined. Primary end point was survival. Secondary end points included technical failure (residual 3/4+ mitral regurgitation), reoperation, New York Heart Association symptoms, 30-day mortality, and other clinical outcomes. Predictors of mortality were determined using multivariable regression analysis. Results: Fifty consecutive patients underwent the MitraClip procedure during the 4-year period. The average age was 83, the Society of Thoracic Surgeons predicted risk of mortality mean was 9.4%, 88% (44/50) had New York Heart Association III/IV symptoms, 86% (43/50) had 4+ mitral regurgitation, and 72% (36/50) had degenerative mitral disease etiology. Echocardiographic data (median [interquartile range] follow-up = 43 ) showed that 86% (43/50) of patients had 2+ or less mitral regurgitation. Sixty percent (24/40) had New York Heart Association I/II symptoms at last follow-up. Predictors of mortality were higher Society of Thoracic Surgeons predicted risk of mortality (P = 0.042, hazard ratio = 1.098) and previous cardiac surgery (P = 0.013, hazard ratio = 3.848). Survival at 1 and 2 years was 75% and 63%, respectively. Conclusions: Many patients with mitral valve regurgitation who are high risk for open surgery can be treated with the MitraClip procedure. In our study, most patients (86%) had a technically successful operation and postoperative outcomes including survival were acceptable.
T
here are currently few treatment options for patients with symptomatic mitral regurgitation (MR) who are at high risk for conventional mitral valve repair or who are deemed inoperable because of severe comorbidities. The MitraClip procedure, a newer promising technology that has been shown to reduce MR, can be performed on patients whose symptoms are not improved with optimal medical management. This transcatheter edge-toedge mitral valve repair has emerged as a safe and effective alternative therapy to open heart surgery. 1, 2 To date, more than 45,000 patients deemed to have prohibitive surgical risk have undergone mitral valve repair using this approach. 3 However, the vast majority have been performed on patients who are low or moderate risk for conventional surgery.
For individuals with moderate to severe MR, the American Heart Association/American College of Cardiology guidelines endorse mitral valve repair or replacement. However, only 60% of these patients present as candidates for surgery. 4 The MitraClip procedure has been shown to be an effective approach with less perioperative morbidity and mortality than conventional surgery. There are reported improvements in New York Heart Association (NYHA) class as well as MR grade after the procedure. 5, 6 According to the American Heart Association/American College of Cardiology guidelines, MitraClip is recommended for patients with degenerative MR who are too high risk for surgery, whereas the European Society of Cardiology guidelines endorse MitraClip placement in patients with functional MR. 1 Our goal was to assess outcomes of patients deemed high risk for surgery with either functional or degenerative MR who underwent MitraClip placement at a single institution where surgical mitral valve replacement is the preferred treatment.
METHODS
A retrospective review of all patients undergoing the MitraClip procedure was conducted between 2014 and 2017 using medical records and established databases. No patients were excluded from the study. Patients were initially seen in clinic by a cardiac surgeon or cardiologist. Those who were deemed high risk for surgery were then presented at a multidisciplinary meeting with multiple cardiologists and surgeons present. Patients who were low or moderate risk for surgery had conventional mitral valve surgery. Those patients deemed high risk because of the Society of Thoracic Surgeons (STS) high scores, frailty, or anatomical considerations (eg, mitral annular calcification) were considered for MitraClip. The primary end point was intermediate-term survival. Secondary end points included technical failure (3/4+ MR) after the procedure, 30-day mortality, reoperation for MitraClip failure, postoperative NYHA class, postoperative atrial fibrillation, sepsis, stroke, acute kidney injury, and readmission to the hospital within 30 days. Echocardiograms were performed postoperatively as standard patient follow-up and in patients who were involved in studies as part of the routine protocols.
Continuous data are reported as mean ± SD or median (interquartile range) as appropriate. Survival estimates were generated using the Kaplan-Meier method. Survival data were obtained for all patients through interrogation of institutional medical records, databases, and obituaries. Operative mortality was defined as death that occurred during the index hospitalization or within 30 days of the operation. Survival data included death from all causes. Univariate and multivariate analyses were used to determine preoperative and intraoperative risk factors that were predictors of mortality and are expressed as hazard ratios (HRs). Statistics were performed with SPSS Version 23.0 (IBM Corp, Armonk, NY USA). A P value of 0.05 or less was considered statistically significant. The study was approved by the Washington University Institutional Review Board committee.
RESULTS
Fifty consecutive patients underwent the MitraClip procedure during the 4-year period. The mean ± SD age was 83 ± 7 years. The mean ± SD STS predicted risk of mortality was 9.4% ± 4%. Forty-four (88%) had NYHA III/IV heart failure symptoms. Severe (4+) MR was present in 86% (43/50), and 72% (36/50) had degenerative MR (Table 1) .
Thirty-day mortality was 4% (2/50). One patient was discharged and returned with severe heart failure symptoms and pulseless electrical activity arrest, and one patient died from cardiogenic shock. One patient experienced an ischemic stroke but recovered strength on the same day. Three patients (6%) had to have surgery for mitral valve replacement after clip placement. In one patient, the clip had a deployment malfunction and was operated on immediately. One patient developed severe MR after 8 months, and one patient developed severe mitral stenosis leading to mitral valve replacement 3 months after the MitraClip. The median (interquartile range) length of stay was 3 (2-5) days. Sixteen percent (8/50) of patients were readmitted within 30 days (Table 2) .
Echocardiographic follow-up (mean ± SD = 0.6 ± 0.1 years) showed 86% (43/50) of patients had either 2+ or less MR at last follow-up (Table 3 ; Figs. 1, 2 ). Sixty percent (24/40) had NYHA I/II symptoms at last follow-up (Fig. 3) . Survival at 1 and 2 years was 75% and 63%, respectively (Fig. 4) . Left ventricular diastolic volume decreased from 141 mL preoperatively to 120 mL after MitraClip placement (P = 0.002). Predictors of mortality were higher STS PROM (P = 0.042, HR = 1.098) and previous cardiac surgery (P = 0.013, HR = 3.848).
DISCUSSION
MitraClip placement is feasible to offer patients who are deemed too high risk to undergo surgery. Survival was acceptable in our study, and most patients (86%) had technically successful procedures performed as demonstrated by MR grade postoperatively.
Our institution performs mitral valve surgery whenever feasible and only patients deemed too high risk for surgery undergo MitraClip placement. During this same period, 918 mitral valve surgeries were performed with standard cardiac surgery techniques. This is important because most published studies on the MitraClip procedure are on lower risk populations that may not have necessarily been too high risk to undergo a surgical operation, and this cohort are much high risk for surgery, because those with low risk were offered standard surgery. Baseline preoperative characteristics were different in our cohort compared with other studies including the EVEREST II trial. 7 The mean ± SD age in this review was 83 ± 7 years compared with 67 ± 13 in the EVEREST II Trial. Furthermore, the mean ± SD STS PROM was 9 ± 4, and 88% of patients (44/50) had NYHA III or IV heart failure symptoms before the procedure. In the EVEREST trial, only 50% (89/178) of patients had NYHA III or IV symptoms before MitraClip placement. 7 Despite these high risks, perioperative complications remained acceptable.
Most patients experienced an improvement in NYHA functional status after placement of the MitraClip. At baseline, 88% (44/50) of patients had NYHA class III or IV heart failure symptoms. After clip placement, the majority had class I and II NYHA symptoms (24/40). Echocardiographic follow-up showed that at 0.6 ± 0.1 years after clip placement, most patients (86%) had 2+ or less MR indicating a technically successful procedure. This is similar to the lower risk cohort in the EVEREST trial, which found that 82% of patients had 2+ or less MR at 1 year. 7 Significant improvement in left ventricular dimensions was noted after MitraClip placement as demonstrated by a decrease in left ventricular diastolic volume from 141 to 120 mL postoperatively (P = 0.002). Studies have shown that most patients undergoing MitraClip placement showed reverse remodeling as demonstrated by a reduction in left ventricular end diastolic volume. This is important because these data reflect the unloading effect of mitral valve repair. 8 Three patients required surgery after their initial procedure. There was a clip deployment malfunction in one patient, which resulted in an emergency mitral valve replacement and then a subsequent redo mitral valve replacement 3 months later. The company has since made modifications to the steps in releasing the clip, and no further issues have been encountered with release of the clip. The second patient developed severe mitral stenosis and subsequently underwent mitral valve replacement 3 months after clip placement, and the third patient developed severe MR and underwent mitral valve replacement 6 months after placement of the MitraClip. A fourth patient underwent clip placement, had initial improvement of MR from 4+ to 2+, and subsequently developed severe MR leading to a second MitraClip placement 8 months later.
Survival was similar to previously published studies. 5 Overall, we found that at 1 and 2 years, survival was 75% and 63%, respectively (Fig. 3) . This was considerably worse survival than the EVEREST II trial, which was presumably the result of a higher risk cohort. 7 Notably, 30-day mortality was 4% (2/50), which is in line with isolated mitral valve surgery. O'Brien et al 9 showed that 30-day mortality in this population was 5.7% in more than 21,000 patients. Twenty-eight percent of our cohort had functional MR, but this cohort becomes increasingly important to consider for MitraClip procedure, specifically when considering the favorable outcomes reported from the COAPT trial where they showed that death or rehospitalization for heart failure at 2 years was 45.7% in patients who underwent the MitraClip procedure vs. 67.9% in the medical therapy arm. 10 Limitations of this study include that it was retrospective in nature and thus subject to the threats inherent to this design. The sample size of our study was limited and likely affected by surgeon bias because only two surgeons routinely performed the procedure. Follow-up is relatively short compared with surgical series; however, in this high-risk cohort, prolonged survival would be surprising, given the multitude of comorbidities in each patient. In addition, although it would be interesting to compare MitraClip patients with a medically managed or surgical cohort, we did not have these data available to us.
In conclusion, most patients in our study underwent a technically successful MitraClip procedure and benefited from improved NYHA functional status. Postoperative complications and intermediate-term survival were acceptable; therefore, in patients deemed too high risk for surgery, the MitraClip remains a feasible option.
